Horizon scanning: Phase III Trial investigating cilengitide fails to meet primary endpoint of increasing overall survival in patients with newly diagnosed glioblastoma

Source: PharmaLive Area: News According to a report by PharmaLive, a phase III trial investigating cilengitide for newly diagnosed glioblastoma has failed to meet the primary endpoint, of increasing overall survival.   The phase III trial CENTRIC, was a randomised, controlled, multi-centre open-label trial which evaluated the safety and efficacy of cilengitide in combination with temozolomide and radiotherapy in more than 500 patients with newly diagnosed glioblastoma and methylated MGMT gene promoter status.
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news